What are the criteria for fine-needle aspiration cytology (FNAC) in a Thyroid Imaging, Reporting and Data System (TI-RADS) 3 nodule?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

TI-RADS 3 Nodule FNAC Criteria

For TI-RADS 3 (mildly suspicious) thyroid nodules, fine-needle aspiration cytology is recommended when the nodule measures ≥2.5 cm, while nodules <2.5 cm should undergo ultrasound surveillance rather than immediate biopsy. 1

Size-Based FNA Thresholds for TI-RADS 3 Nodules

The critical size threshold for TI-RADS 3 nodules is 2.5 cm. 1 This recommendation balances the low malignancy risk of mildly suspicious nodules against the need to detect clinically significant cancers.

  • Nodules ≥2.5 cm: Proceed with ultrasound-guided FNA biopsy 1
  • Nodules 1.5-2.4 cm: Ultrasound surveillance is recommended rather than immediate FNA 1
  • Nodules <1.5 cm: No FNA indicated; surveillance only 1

The rationale is that TI-RADS 3 nodules carry a low cancer risk, with negative predictive values of 94.6% for benign disease 2. Research demonstrates that lowering the size threshold from 1.5 cm to 1.0 cm for TI-RADS 3 nodules would capture only 7 additional malignant nodules but would add 118 benign nodules to follow-up, representing an unfavorable risk-benefit ratio 3.

High-Risk Clinical Features That Lower the FNA Threshold

Even for TI-RADS 3 nodules <2.5 cm, FNA should be considered when specific high-risk clinical factors are present: 1

  • History of head and neck irradiation - substantially increases baseline malignancy risk 1
  • Family history of thyroid cancer - particularly medullary thyroid carcinoma or familial syndromes 1
  • Suspicious cervical lymphadenopathy - suggests possible nodal metastases 1
  • Subcapsular location - increases risk of extrathyroidal extension 1

These clinical contexts modify the pretest probability sufficiently to warrant tissue diagnosis despite the lower TI-RADS score.

Ultrasound Features Defining TI-RADS 3

TI-RADS 3 nodules typically have mildly suspicious sonographic characteristics but lack the multiple high-risk features seen in TI-RADS 4-5 categories. 1 Common patterns include:

  • Solid composition with isoechoic or mildly hypoechoic appearance 1
  • Smooth or mostly smooth margins 1
  • Absence of microcalcifications 1
  • No evidence of extrathyroidal extension 1

Surveillance Protocol for TI-RADS 3 Nodules Not Meeting FNA Criteria

For TI-RADS 3 nodules <2.5 cm without high-risk features, ultrasound surveillance is the appropriate management: 1

  • Initial follow-up ultrasound at 12 months 1
  • Subsequent surveillance intervals based on stability 1
  • FNA should be performed if the nodule grows ≥20% in two dimensions with a minimum increase of 2 mm 1

Critical Pitfalls to Avoid

Do not perform FNA on TI-RADS 3 nodules <2.5 cm without high-risk features. This leads to overdiagnosis and overtreatment of clinically insignificant cancers, particularly papillary microcarcinomas that have excellent prognosis with observation alone. 1

Do not rely on thyroid function tests (TSH, T3, T4) to determine malignancy risk. Most thyroid cancers present with normal thyroid function, making these tests unhelpful for risk stratification. 1

Ensure ultrasound guidance for all FNA procedures. Ultrasound-guided FNAB has significantly lower non-diagnostic rates compared to freehand technique and is the preferred diagnostic method for accuracy, economy, and safety. 1, 4

Special Consideration for Subcentimeter TI-RADS 3 Nodules

Research on subcentimeter nodules demonstrates that TI-RADS scores of 1-2 had 0% risk of papillary thyroid carcinoma, while TI-RADS 3 nodules showed intermediate risk. 5 However, even for high-scoring subcentimeter nodules, the current evidence supports surveillance over immediate biopsy unless high-risk clinical features are present. 1, 6

The nondiagnostic rate for subcentimeter nodules (7%) is higher than for larger nodules (3%), further supporting the size-based threshold approach. 5

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.